Company ZYUS Life Sciences Corporation

Equities

ZYUS

CA9899601095

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 01:21:30 2024-04-17 pm EDT			5-day change	1st Jan Change
1 ^CAD	+3.09%		+3.09%	+11.11%

Mar. 05	Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets	MT
Feb. 20	Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate	MT

ZYUS Life Sciences Corporation is a Canada-based life sciences company. The Company is focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and exempt market therapeutics. Through clinical research, it is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, the Company delivers cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The Company is also focused on commercialization of its exempt market therapeutics, such as cannabinoid oils, soft gel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.

Managers	Title	Age	Since
Brent Zettl FOU	Founder	61	18-03-31
John Hyshka DFI	Director of Finance/CFO	-	-
Lionel Marks de Chabris CTO	Chief Tech/Sci/R&D Officer	-	-
Keith Carpenter CIO	Chief Investment Officer	-	18-03-31
Tim Miller IRC	Investor Relations Contact	-	Oct. 31

Members of the board	Title	Age	Since
Wayne Brownlee BRD	Director/Board Member	71	23-06-28
John Knowles BRD	Director/Board Member	68	20-08-31
Brent Zettl FOU	Founder	61	18-03-31
Richard Hoyt CHM	Chairman	70	20-08-31
Charlotte Hepburn BRD	Director/Board Member	-	-
Garnette Joyce Weber BRD	Director/Board Member	-	21-07-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	70,847,396	29,699,319 ( 41.92 %)	0	41.92 %

Name	Equities	%	Valuation
Brent Zettl 48.23 %	34,173,073	48.23 %	26 M $
Wayne Brownlee 4.594 %	3,254,628	4.594 %	2 M $
Entrust Global Ltd. 4.309 %	3,052,755	4.309 %	2 M $
Charlotte Hepburn 3.326 %	2,356,259	3.326 %	2 M $
John Knowles 0.4160 %	294,719	0.4160 %	221 039 $
Charles Burns 0.3867 %	274,000	0.3867 %	205 500 $
Michael Detlefsen 0.2562 %	181,500	0.2562 %	136 125 $
Greg Nuttall 0.2400 %	170,000	0.2400 %	127 500 $
Richard Hoyt 0.2133 %	151,108	0.2133 %	113 331 $
Keith Carpenter 0.1767 %	125,178	0.1767 %	93 884 $

ZYUS Life Sciences Corp.

407 Downey Road Suite 204

S7N 4L8, Saskatoon

http://www.zyus.com

address ZYUS Life Sciences Corporation(ZYUS)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1 CAD

Average target price

2.75 CAD

Spread / Average Target

+175.00%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ZYUS LIFE SCIENCES CORPORATION	+11.11%	51.53M
IQVIA HOLDINGS INC.	-1.95%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.94%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.75%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-23.97%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.92%	11.68B
MEDPACE HOLDINGS, INC.	+21.18%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.41%	11.15B

Other Biotechnology & Medical Research